Physician-Led • Evidence-Based • Clinical Decision Support

Protect Muscle While Losing Weight on GLP-1 Therapy

For patients using GLP-1 and incretin-based weight-loss therapy.

Weight loss should not come at the expense of lean tissue. MyoGuard provides physician-guided muscle preservation support through the Sarcopenia Risk Index (SRI).

Generate My Preliminary SRI →

No account required • Takes about 60 seconds

Built on: STEP Trials • EWGSOP2 • PROT-AGE • Peer-Reviewed Evidence

Muscle Protection Assessment

Powered by the Sarcopenia Risk Index (SRI)

4 fields remaining

Body metrics

GLP-1 therapy

Symptoms & lifestyle

GI symptoms on current dose
Select none if no symptomsGI burden directly impairs nutrient absorption and protein adequacy
Activity level *

Recovery environment

Recovery Environment Indicator (informational)
7hMild recovery deficit
3h6h9h14h

Typical adult range: 5–9 hours

Sleep duration is displayed as a recovery context indicator. Nocturnal GH and IGF-1 secretion support muscle protein synthesis — adequate sleep optimises your protocol outcomes. This parameter is not incorporated into the sarcopenia risk score.

MyoGuard Clinical Oversight · For educational use only · Not a substitute for clinical consultation

How MyoGuard Helps

Real-time sarcopenia risk

SRI generated against your GLP-1 dose stage and clinical protein floor

Personalised protein targets

Protein and fibre guidance calibrated to your weight, dose, and GI burden

Evidence-based supplement guidance

Protocol stack grounded in peer-reviewed nutrition science

Continuous adherence monitoring

Weekly check-ins with longitudinal tracking of your muscle preservation indicators